skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Bovine Immunoglobulin Orally with Modified Doses of Rifaximin for Advanced Cirrhotics in Overt Hepatic Encephalopathy: A Randomized Placebo Control Prospective Clinical Pilot Trial. (BRAIN Trial): 907

The American journal of gastroenterology, 2018-10, Vol.113 (Supplement), p.S503-S505 [Peer Reviewed Journal]

Copyright Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins Oct 2018 ;ISSN: 0002-9270 ;EISSN: 1572-0241 ;DOI: 10.14309/00000434-201810001-00907

Full text available

Citations Cited by
  • Title:
    Bovine Immunoglobulin Orally with Modified Doses of Rifaximin for Advanced Cirrhotics in Overt Hepatic Encephalopathy: A Randomized Placebo Control Prospective Clinical Pilot Trial. (BRAIN Trial): 907
  • Author: Basu, Patrick ; John, Nimy ; Aloysius, Mark
  • Subjects: Immunoglobulins
  • Is Part Of: The American journal of gastroenterology, 2018-10, Vol.113 (Supplement), p.S503-S505
  • Description: Introduction: Overt Hepatic Encephalopathy (OHE) is an integral clinical syndrome in decompensated cirrhosis with significant morbidity. Recurrent hospitalization carries Hospital-acquired infections with threatens risk and further decompensation. Imposes hazards: driving skill, domestic affair, social conduct affecting Global QOL score. Rifaximin, lactulose, Metronidazole and are existing therapy of choice. Several others have been postulated: LOPA, Probiotics, Rivastigmine with moderate efficacy. This clinical trial will evaluate the added efficacy and shorten the course of Rifaximin in clinically OHE. Methods: Overt Hepatic Encephalopathy patients recruited in three groups: A single center: dedicated Psychologist, Dedicated lab; single driving instructor, 3 arm study (groups A, B, and C), n=20 in each. Group A=Rifaximin 550mg BID,BCAA (Branched Chain Amino Acids) x 3 months Group B=Rifaximin 550mg BID,Bovine IG x 3 months Group C=Rifaximin 550mg BID,Bovine IG,BCAA x 3 months Exclusion Criteria: MELD 23 or greater, Uncontrolled DM, SBP Severe Constipation HCC CDAD Active drug or Alcohol use On DAAs therapy PBC PSC Schistosoma AIH Post-Transplant HBV HIV Results: Table 1 Primary Endpoint Global Encephalopathy score Group A median 43% Group B median 63% Group C median 66% Secondary Endpoint impaired Social skill (driving test) Group A median 21% Group B median 33% Group C median 31% Recurrent Hospitalization Time in six months Group A median 65% Group B median 68% Group C median 71% Conclusion: For morbidity in CLF and ACLF with Cognitive and Psychosocial impairment rifaximin is the standard of care. Oral Bovine Immunoglobulin has been used as gut sterilizer and generates Gut specific immune Restitution. This study evaluates adding Oral Bovine immunoglobulin in OHE and concludes that it is not beneficial over the standard of care and not cost effective.
  • Publisher: New York: Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
  • Language: English
  • Identifier: ISSN: 0002-9270
    EISSN: 1572-0241
    DOI: 10.14309/00000434-201810001-00907
  • Source: ProQuest Central
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait